Trial Profile
A retrospective study to evaluate the long-tem efficacy and treatment response to mepolizumab in patients with platelet derived growth factor alpha (PDGFRA)-negative hypereosinophilic syndrome
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Mar 2016
Price :
$35
*
At a glance
- Drugs Mepolizumab (Primary)
- Indications Hypereosinophilic syndrome
- Focus Therapeutic Use
- 17 Mar 2016 New trial record
- 07 Mar 2016 Results presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology